Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years ...

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial ...

Dr. Ryuma Tanaka presented the results of a retrospective study of patients with metastatic hormone sensitive prostate cancer (mHSPC) and the impact of delayed administration of androgen receptor ...

Given the link between CDK12 loss and castration resistance in human PCa, investigators analyzed androgen receptor (AR) ...

Among patients with metastatic hormone-sensitive prostate cancer (mHSPC), patients with de novo vs secondary mHSPC are more likely to progress to castration-resistant disease.

The androgen receptor is often activated despite resistance to available androgen receptor signaling inhibitors, with androgen receptor splice variants being detectable, and androgen mutations being ...

Given the link between CDK12 loss and castration resistance in human PCa, investigators analyzed androgen receptor (AR) signaling in CDK12KO organoids. The organoids were treated with 5,6 ...

Using progesterone receptor (PR)- and androgen receptor (AR)-mediated transactivation ... USA) and GAPDH (14C10; Cell Signaling Technology, Inc.), respectively. Clarity Western ECL Substrate (Bio-Rad ...